Details
| Translated title of the contribution | Nonalcoholic fatty liver disease |
|---|---|
| Original language | German |
| Pages (from-to) | 85-94 |
| Number of pages | 10 |
| Journal | Diabetes, Stoffwechsel und Herz |
| Volume | 25 |
| Issue number | 2 |
| Publication status | Published - Apr 2016 |
Abstract
Nonalcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis without significant alcohol-related or other causes of secondary steatosis, and is the most widespread liver disease in the industrialised world with around 20-30 % of the global population affected. NAFLD ranges from steatosis on its own (NAFL) to nonalcoholic steatohepatitis (NASH) and cirrhosis, and on towards hepatocellular carcinoma (HCC). NAFLD development is multifactorial with influences including genetic and epigenetic, hormonal and environmental factors, and especially lifestyle. Peripheral and hepatic insulin resistance is a common link to the established risk factors that include visceral obesity, hyper- caloric diet, and lack of physical activity. NAFLD is not an isolated liver disease as it causes a variety of metabolic disorders including type 2 diabetes, kidney disease, and atherosclerotic issues such as coronary heart disease. NAFLD is diagnosed using imaging procedures, especially sonography, and biochemical and anthropometric data in routine clinical practice; treatment involves lifestyle intervention consisting of exercise and nutritional therapy.
ASJC Scopus subject areas
- Medicine(all)
- Internal Medicine
- Medicine(all)
- Endocrinology, Diabetes and Metabolism
- Biochemistry, Genetics and Molecular Biology(all)
- Endocrinology
Sustainable Development Goals
Cite this
- Standard
- Harvard
- Apa
- Vancouver
- BibTeX
- RIS
In: Diabetes, Stoffwechsel und Herz, Vol. 25, No. 2, 04.2016, p. 85-94.
Research output: Contribution to journal › Article › Research
}
TY - JOUR
T1 - Nichtalkoholische Fettlebererkrankung
AU - Worm, Nicolai
AU - Stein, J.
AU - Ströhle, A.
N1 - Copyright: Copyright 2017 Elsevier B.V., All rights reserved.
PY - 2016/4
Y1 - 2016/4
N2 - Nonalcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis without significant alcohol-related or other causes of secondary steatosis, and is the most widespread liver disease in the industrialised world with around 20-30 % of the global population affected. NAFLD ranges from steatosis on its own (NAFL) to nonalcoholic steatohepatitis (NASH) and cirrhosis, and on towards hepatocellular carcinoma (HCC). NAFLD development is multifactorial with influences including genetic and epigenetic, hormonal and environmental factors, and especially lifestyle. Peripheral and hepatic insulin resistance is a common link to the established risk factors that include visceral obesity, hyper- caloric diet, and lack of physical activity. NAFLD is not an isolated liver disease as it causes a variety of metabolic disorders including type 2 diabetes, kidney disease, and atherosclerotic issues such as coronary heart disease. NAFLD is diagnosed using imaging procedures, especially sonography, and biochemical and anthropometric data in routine clinical practice; treatment involves lifestyle intervention consisting of exercise and nutritional therapy.
AB - Nonalcoholic fatty liver disease (NAFLD) is defined as hepatic steatosis without significant alcohol-related or other causes of secondary steatosis, and is the most widespread liver disease in the industrialised world with around 20-30 % of the global population affected. NAFLD ranges from steatosis on its own (NAFL) to nonalcoholic steatohepatitis (NASH) and cirrhosis, and on towards hepatocellular carcinoma (HCC). NAFLD development is multifactorial with influences including genetic and epigenetic, hormonal and environmental factors, and especially lifestyle. Peripheral and hepatic insulin resistance is a common link to the established risk factors that include visceral obesity, hyper- caloric diet, and lack of physical activity. NAFLD is not an isolated liver disease as it causes a variety of metabolic disorders including type 2 diabetes, kidney disease, and atherosclerotic issues such as coronary heart disease. NAFLD is diagnosed using imaging procedures, especially sonography, and biochemical and anthropometric data in routine clinical practice; treatment involves lifestyle intervention consisting of exercise and nutritional therapy.
KW - Insulin resistance
KW - Lifestyle
KW - Nonalcoholic fatty liver disease
KW - Nutritional therapy
UR - http://www.scopus.com/inward/record.url?scp=84973367444&partnerID=8YFLogxK
M3 - Artikel
VL - 25
SP - 85
EP - 94
JO - Diabetes, Stoffwechsel und Herz
JF - Diabetes, Stoffwechsel und Herz
SN - 1861-7603
IS - 2
ER -